Hedgehog signaling pathway

Hedgehog Signaling - The 'Sonic' Boom

• Core Components:

  • Ligand: Sonic Hedgehog (SHH)
  • Receptors: Patched (PTCH1) [inhibitory] & Smoothened (SMO) [activating]
  • Effector: GLI family transcription factors

• Mechanism of Action:

  • OFF State (No SHH): PTCH1 inhibits SMO. The GLI protein is cleaved into a repressor form (GLI-R).
  • ON State (SHH present): SHH binding to PTCH1 relieves SMO inhibition. Active SMO allows full-length GLI (GLI-A) to translocate to the nucleus and activate target genes.

• Clinical Relevance:

  • Mutations causing constitutive activation are linked to medulloblastoma and basal cell carcinoma.
  • Gorlin Syndrome: Inherited PTCH1 mutation.

⭐ Vismodegib is a key pharmacologic inhibitor of SMO, used in the treatment of advanced basal cell carcinoma.

Mechanism of Action - An On/Off Switch

• "Off" State (No Hh Ligand):

  • Patched (PTCH1) receptor actively inhibits Smoothened (SMO), preventing its localization to the primary cilium.
  • The transcription factor GLI is proteolytically cleaved into a repressor form (GLI-R).
  • GLI-R translocates to the nucleus and suppresses the transcription of Hh target genes.

• "On" State (Hh Ligand Present):

  • Hedgehog (e.g., SHH) binds to PTCH1, causing its internalization and degradation.
  • Inhibition on SMO is lifted; SMO accumulates in the primary cilium.
  • Active SMO prevents GLI cleavage, allowing the full-length activator form (GLI-A) to accumulate.
  • GLI-A enters the nucleus and activates genes controlling cell fate, proliferation, and survival.

⭐ Constitutive activation of the Hedgehog pathway due to mutations in PTCH1 or SMO is the primary driver of basal cell carcinoma. This is the therapeutic target for SMO inhibitors like Vismodegib.

Clinical Correlations - When Hedgehogs Go Rogue

Mutations causing constitutive Hedgehog pathway activation lead to uncontrolled cell proliferation and cancer. This occurs via inactivating mutations in PTCH or activating mutations in SMO.

• Gorlin Syndrome (Nevoid Basal Cell Carcinoma Syndrome):

  • Autosomal dominant inherited mutation in the PTCH1 gene.
  • Key features: Multiple basal cell carcinomas (BCCs) appearing early in life, odontogenic keratocysts in the jaw, calcified falx cerebri, and palmar or plantar pits.

• Sporadic Cancers:

  • Basal Cell Carcinoma: The most common human cancer. Most cases have acquired mutations in PTCH1 or SMO.
  • Medulloblastoma: The most common malignant pediatric brain tumor.

⭐ Vismodegib & Sonidegib are Hedgehog pathway inhibitors used for advanced BCC, acting by inhibiting the SMO protein.

Pharmacology - Pathway Inhibitors

• SMO Inhibitors
  • Vismodegib, Sonidegib
  • Mechanism: Bind to and inhibit the Smoothened (SMO) protein, preventing downstream signal activation.
  • Clinical Use: Advanced Basal Cell Carcinoma (BCC), especially metastatic or locally advanced cases.

⭐ Teratogenicity is a major side effect, reflecting the pathway's critical role in embryonic development (e.g., holoprosencephaly).

High‑Yield Points - ⚡ Biggest Takeaways

• The Hedgehog (Hh) pathway is crucial for embryonic development, including limb patterning and neural tube formation.
• Without the Hh ligand, the Patched (PTCH1) receptor actively inhibits Smoothened (SMO).
• Hh binding to PTCH1 releases this inhibition, activating SMO and subsequently the GLI transcription factors.
• Constitutive pathway activation is a key driver of basal cell carcinoma and medulloblastoma.
• Mutations can lead to severe developmental defects like holoprosencephaly.
• SMO inhibitors (e.g., Vismodegib) are targeted therapies for Hh-driven cancers.